2형 당뇨병 : 시장 인사이트, 역학 및 시장 예측(2036년)

Type 2 Diabetes Mellitus (T2DM) Insights and Trends

• Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder marked by insulin resistance and progressive B-cell dysfunction, leading to persistent hyperglycemia. Unlike type 1 diabetes, T2DM develops primarily from impaired insulin action, initially compensated by increased insulin secretion until B-cell failure occurs. Its global rise is driven by aging populations and lifestyle changes such as physical inactivity and high-calorie diets, contributing to significant microvascular and macrovascular complications.
• Type 2 diabetes can develop at any age, including during childhood, but it is more common among middle-aged and older adults. The risk increases with age, particularly after 45 years, as well as with a family history of diabetes and overweight or obesity.
• More than 40 million Americans have diabetes, equivalent to approximately 1 in 8 people, and around 90%-95% of these individuals have type 2 diabetes. Type 2 diabetes most commonly develops in people aged 45 years and older; however, an increasing number of children, adolescents, and young adults are also developing the condition.
• GLP-1 may play a broader cardiometabolic role beyond glucose control, with GLP-1 receptor signaling potentially contributing to blood pressure regulation and sympathetic activity, thereby highlighting the potential of GLP-1-based therapies to address both glycemic control and cardiovascular risk factors.
• Real-world evidence highlights a significant GLP-1 therapy adherence challenge, with up to 64% of patients discontinuing treatment within 1 year and 74% by year 2, underscoring the need for more convenient oral alternatives that could reduce injection burden and potentially improve long-term treatment persistence.
• The T2DM GLP-1 pipeline includes promising next-generation candidates such as retatrutide (Eli Lilly), CagriSema (Novo Nordisk), and survodutide (Boehringer Ingelheim), among others. By leveraging multi-receptor agonism and complementary metabolic pathways, these therapies aim to deliver enhanced glycemic control, weight-loss efficacy, and broader cardiometabolic benefits, potentially addressing key unmet needs in T2DM management.
• The marketed T2DM therapies include semaglutide (OZEMPIC, RYBELSUS), liraglutide (VICTOZA), dulaglutide (TRULICITY), tirzepatide (MOUNJARO), empagliflozin (JARDIANCE), dapagliflozin (FARXIGA), canagliflozin (INVOKANA), sitagliptin (JANUVIA), linagliptin (TRADJENTA), and saxagliptin (ONGLYZA). These therapies provide established glycemic control, with several also demonstrating weight-management, cardiovascular, and kidney-related benefits, supporting their continued use across the evolving T2DM treatment landscape.

Type 2 Diabetes Mellitus (T2DM) Market Size and Forecast in the 7MM

DelveInsight's 'Type 2 Diabetes Mellitus (T2DM) - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the T2DM, historical and forecasted epidemiology, as well as the T2DM market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The T2DM market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, T2DM patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in T2DM and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Type 2 Diabetes Mellitus (T2DM) Market

Rising T2DM Prevalence

The increasing prevalence of T2DM is a key driver of T2DM market expansion, supported by rising obesity rates, sedentary lifestyles, aging populations, increasing disease awareness and diagnosis, and growing adoption of newer therapies that provide effective glycemic control alongside weight-management, cardiovascular, and kidney benefits.

Rising Opportunities in Novel T2DM Therapies

The substantial unmet need in T2DM is creating opportunities for next-generation therapies, oral treatment options, and multi-target metabolic approaches aimed at improving glycemic control, supporting sustained weight loss, reducing cardiovascular and kidney-related complications, and enhancing treatment adherence, thereby addressing limitations associated with conventional T2DM therapies.

Type 2 Diabetes Mellitus (T2DM) Understanding and Treatment Algorithm

Type 2 Diabetes Mellitus (T2DM) Overview and Diagnosis

T2DM is a chronic, progressive metabolic disorder characterized by insulin resistance and inadequate insulin secretion, resulting in persistently elevated blood glucose levels and an increased risk of microvascular and macrovascular complications. It commonly develops in adulthood but is increasingly diagnosed in children, adolescents, and younger adults. Major risk factors include overweight or obesity, physical inactivity, advancing age, family history of diabetes, and certain metabolic conditions. Long-term management involves lifestyle modification, glucose-lowering therapies, and regular monitoring to achieve glycemic control and reduce the risk of cardiovascular, kidney, retinal, and neuropathic complications.

T2DM is diagnosed through blood glucose testing, including HbA1c, fasting plasma glucose, oral glucose tolerance testing, or random plasma glucose testing in patients with characteristic symptoms. Diagnosis is based on established clinical criteria, with repeat testing generally used to confirm abnormal results in the absence of unequivocal hyperglycemia. Additional assessments may include lipid profile, kidney function, blood pressure, and screening for diabetes-related complications to support comprehensive disease management and treatment planning.

Type 2 Diabetes Mellitus (T2DM) Treatment

The primary goals of T2DM treatment are to achieve and maintain glycemic control, reduce the risk of diabetes-related complications, support healthy weight management, and improve long-term quality of life. Current management includes lifestyle modifications and glucose-lowering therapies, with agents such as semaglutide (OZEMPIC, RYBELSUS), tirzepatide (MOUNJARO), empagliflozin (JARDIANCE), dapagliflozin (FARXIGA), sitagliptin (JANUVIA), and insulin widely used across different stages of disease management. Emerging therapies, including oral metabolic agents, next-generation incretin-based therapies, and multi-receptor agonists such as retatrutide, CagriSema, and survodutide, aim to enhance glycemic control, promote weight loss, and provide broader cardiovascular and kidney benefits while improving treatment convenience and adherence.

Type 2 Diabetes Mellitus (T2DM) Unmet Needs

The section "unmet needs of T2DM" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Durable and Sustained Glycemic Control

2. Effective and Long-Term Weight Management

3. Comprehensive Cardiovascular and Kidney Protection

4. Improved Treatment Adherence and Patient Convenience, and others.....

Type 2 Diabetes Mellitus (T2DM) Epidemiology

Key Findings from Type 2 Diabetes Mellitus (T2DM) Epidemiological Analysis and Forecast

• According to the Centers for Disease Control and Prevention (CDC), over 38 million Americans around 1 in 10 have diabetes, with 90% to 95% of cases being type 2 diabetes. While it typically develops in adults over 45, an increasing number of children, teens, and young adults are now being diagnosed.
• As per the research study, the prevalence of T2DM in Germany is approximately 9.9%. The prevalence increases sharply from age 50 to 80, with the highest number of new diagnoses occurring around age 85.
• In France, the prevalence of T2DM is 4.6% in the general population, with rates increasing substantially with age. Approximately one in five men aged 70 to 85 years and one in seven women aged 75 to 85 years receive pharmacological treatment for T2DM.
• Using data from the National Health and Nutrition Examination Survey (NHANES), the CDC estimated that 32.7% of US adolescents aged 12-17 years had prediabetes in 2023.

Type 2 Diabetes Mellitus (T2DM) Drug Chapters & Competitive Analysis

The T2DM drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the T2DM treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the T2DM therapeutics market.

Approved Therapies for Type 2 Diabetes Mellitus (T2DM)

Bexagliflozin (BRENZAVVY): TheracosBio

It is a SGLT2 inhibitor approved by the US FDA in January 2023 as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. By inhibiting SGLT2 in the renal proximal tubule, it reduces glucose reabsorption and lowers the renal threshold for glucose, leading to increased urinary glucose excretion and improved blood sugar control. BRENZAVVY is administered orally. It also stands out as the lowest priced SGLT2 inhibitor currently available in the US market.

Semaglutide (OZEMPIC/RYBELSUS/WEGOVY): Novo Nordisk

Semaglutide is a GLP-1 receptor agonist marketed by Novo Nordisk under different brand names with distinct FDA-approved indications.

OZEMPIC: Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.

RYBELSUS: Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for these events.

Type 2 Diabetes Mellitus (T2DM) Pipeline Analysis

CagriSema: Novo Nordisk

CagriSema, developed by Novo Nordisk, is a once-weekly subcutaneous fixed-dose combination of the long-acting amylin analogue cagrilintide (2.4 mg) and the GLP-1 receptor agonist semaglutide (2.4 mg). It is being investigated for the treatment of adults with type 2 diabetes mellitus (T2DM), with the potential to improve glycemic control and provide additional benefits in body weight and cardiometabolic risk factors.

Survodutide (BI 456906): Boehringer Ingelheim

Survodutide (BI 456906), developed by Boehringer Ingelheim, is a glucagon receptor (GCGR)/GLP-1 receptor dual agonist being evaluated for T2DM. By targeting both receptors, survodutide is designed to enhance glucose control while also supporting weight reduction and broader metabolic improvements. The compound is currently in Phase III development.

Type 2 Diabetes Mellitus (T2DM) Key Players, Market Leaders and Emerging Companies

• TheracosBio
• Novo Nordisk
• Eli Lilly
• Boehringer Ingelheim
• AstraZeneca
• Johnson & Johnson
• Merck, and others.

Type 2 Diabetes Mellitus (T2DM) Drug Updates

• In June 2026, Novo Nordisk reported positive Phase III results from the REIMAGINE 1-3 trials, demonstrating that CagriSema achieved significant reductions in HbA1c and body weight in adults with type 2 diabetes. The findings were presented at the ADA 2026 Scientific Sessions
• In April 2026, Eli Lilly reported positive Phase III ACHIEVE-4 results for orforglipron in adults with type 2 diabetes and overweight/obesity at elevated cardiovascular risk. The trial met its primary endpoint, showing non-inferior MACE risk versus insulin glargine, while delivering greater reductions in A1C and body weight through 104 weeks. All-cause mortality was also lower with FOUNDAYO, although this analysis was not multiplicity-controlled.
• In February 2026, Novo Nordisk announced CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial.

Drug Class Insights

Type 2 Diabetes Mellitus (T2DM) Market Outlook

The T2DM treatment landscape is evolving toward a patient-centered, multifaceted approach encompassing lifestyle modification, glucose monitoring, pharmacotherapy, and, in selected patients, metabolic surgery. Lifestyle interventions, including healthy diet, regular physical activity, and weight management, remain the foundation of care; however, the growing prevalence of T2DM and increasing need for durable glycemic control continue to drive demand for pharmacologic therapies. Metformin remains a widely used first-line option, while sulfonylureas, glinides, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and insulin are utilized based on glycemic needs, comorbidities, safety, and patient preferences. The market is increasingly shifting toward therapies that provide benefits beyond glucose lowering, particularly cardiovascular and renal protection and weight reduction, supporting continued uptake of SGLT2 inhibitors and GLP-1 receptor agonists. Emerging combination and multi-agonist therapies are expected to further intensify competition by targeting both glycemic control and metabolic outcomes. Insulin remains an important treatment option for patients with inadequate control despite non-insulin therapies, while continuous glucose monitoring and other digital tools are supporting more personalized treatment optimization. Metabolic surgery also represents an established option for eligible patients with obesity and poorly controlled T2DM. Overall, the T2DM market is expected to be shaped by rising disease burden, increasing treatment intensification, demand for therapies with cardiometabolic benefits, and continued innovation in combination and next-generation therapies.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Type 2 Diabetes Mellitus (T2DM) (2022-2036 Forecast)

The T2DM treatment landscape comprises therapies targeting multiple pathways involved in glucose regulation, insulin sensitivity, renal glucose handling, and metabolic control. Established therapies include biguanides, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, thiazolidinediones, GLP-1 receptor agonists, and insulin, while emerging therapies increasingly focus on multi-target mechanisms and improved cardiometabolic outcomes.

• Insulin Sensitizers and Insulin Secretagogues: Established therapies such as metformin and pioglitazone improve glycemic control primarily by reducing hepatic glucose production and enhancing insulin sensitivity. Sulfonylureas and glinides stimulate pancreatic insulin secretion and provide effective glucose lowering, although their use may be limited by risks such as hypoglycemia and weight gain.
• Incretin-Based Therapies: DPP-4 inhibitors such as sitagliptin and linagliptin enhance endogenous incretin activity, while GLP-1 receptor agonists such as semaglutide, dulaglutide, and liraglutide provide potent glucose lowering with additional weight-loss and cardiometabolic benefits. Increasing innovation is focused on dual and multi-agonist therapies that simultaneously target multiple metabolic pathways to improve glycemic control and weight management.
• SGLT2 Inhibitors: Agents such as empagliflozin and canagliflozin reduce renal glucose reabsorption, thereby increasing urinary glucose excretion and lowering blood glucose levels. Beyond glycemic control, this class provides important cardiovascular and renal benefits, supporting its growing role in patients with T2DM and associated cardiovascular or kidney disease.

Overall, metformin, SGLT2 inhibitors, and GLP-1 receptor-based therapies remain key pillars of T2DM management, while dual- and multi-target metabolic therapies are driving innovation. The emergence of novel combination therapies and next-generation incretin-based agents is expected to broaden treatment options and potentially reshape the T2DM market by addressing glycemic control, weight management, cardiovascular and renal outcomes, and other persistent unmet needs beyond conventional glucose lowering.

Type 2 Diabetes Mellitus (T2DM) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the T2DM market's uptake by drugs, patient uptake by therapy, and sales of each drug.

Type 2 Diabetes Mellitus (T2DM) Therapies Price Scenario & Trends

Pricing and analogue assessment of T2DM therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for Type 2 Diabetes Mellitus (T2DM)

To keep up with T2DM market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the T2DM emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in T2DM, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the University of Mississippi Medical Center, University of Bologna, and Teikyo University School of Medicine, etc. were contacted. Their opinion helps understand and validate current and emerging T2DM therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in T2DM.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of T2DM, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of T2DM, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the T2DM market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM T2DM market.

Report Insights

• T2DM Patient Population Forecast
• T2DM Therapeutics Market Size
• T2DM Pipeline Analysis
• T2DM Market Size and Trends
• T2DM Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year Forecast
• T2DM Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• T2DM Treatment Addressable Market (TAM)
• T2DM Competitive Landscape
• T2DM Major Companies Insights
• T2DM Price Trends and Analogue Assessment
• T2DM Therapies Drug Adoption/Uptake
• T2DM Therapies Peak Patient Share analysis

Report Assessment

• T2DM Current Treatment Practices
• T2DM Unmet Needs
• T2DM Clinical Development Analysis
• T2DM Emerging Drugs Product Profiles
• T2DM Market Attractiveness
• T2DM Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the T2DM market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of T2DM?
• What are the disease risks, burdens, and unmet needs of T2DM? What will be the growth opportunities across the 7MM concerning the patient population with T2DM?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of T2DM? What are the current guidelines for treating T2DM in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the T2DM market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Upcoming Key Catalysts
• 4.2. Key Transactions And Collaborations
• 4.3. News Flow

5. Epidemiology and Market Forecast Methodology

6. Type 2 Diabetes Mellitus (T2DM) Market Overview at a Glance

• 6.1. Clinical Landscape Analysis (By Phase, Molecule Type, and RoA)
• 6.2. Market Share (%) Distribution of T2DM By Therapies in the 7MM, in 2025
• 6.3. Market Share (%) Distribution of T2DM By Therapies in the 7MM, in 2036

7. Disease Background and Overview of Type 2 Diabetes Mellitus (T2DM)

• 7.1. Introduction
• 7.2. Sign and symptoms
• 7.3. Risk Factors
• 7.4. Subtypes of T2DM
• 7.5. Pathophysiology
  • 7.5.1. Genetics of T2DM
• 7.7. Biomarkers
• 7.8. Diagnosis
  • 7.8.1. Symptoms Rating Scales in T2DM
  • 7.8.2. Algorithm for Differential Diagnosis of Negative Symptoms
  • 7.8.3. Differential Diagnosis

8. Treatment and Management

• 8.1. Treatment Algorithm
• 8.2. Guidelines

9. Epidemiology and Patient Population of Type 2 Diabetes Mellitus (T2DM)

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. Type 2 Diabetes Mellitus Prevalent Cases in the 7MM
• 9.4. The United States
  • 9.4.1. Total Prevalent Cases of Type 2 Diabetes Mellitus in the United States
  • 9.4.2. Total Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus in the United States
  • 9.4.3. Age-specific Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus in the United States
  • 9.4.4. Gender-specific Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus in the United States
  • 9.4.5. Treated Cases of Type 2 Diabetes Mellitus in the United States
• 9.5. EU4 and the UK
  • 9.5.1. Total Prevalent Cases of Type 2 Diabetes Mellitus in EU4 and the UK
  • 9.5.2. Total Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus in EU4 and the UK
  • 9.5.3. Age-specific Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus in EU4 and the UK
  • 9.5.4. Gender-specific Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus in EU4 and the UK
  • 9.5.5. Treated Cases of Type 2 Diabetes Mellitus in EU4 and the UK
• 9.6. Japan
  • 9.6.1. Total Prevalent Cases of Type 2 Diabetes Mellitus in Japan
  • 9.6.2. Total Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus in Japan
  • 9.6.3. Age-specific Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus in Japan
  • 9.6.4. Gender-specific Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus in Japan
  • 9.6.5. Treated Cases of Type 2 Diabetes Mellitus in Japan

10. Patient Journey of Type 2 Diabetes Mellitus (T2DM)

11. Marketed Therapies

• 11.1. Competitive landscape of marketed therapies
• 11.2. Semaglutide (OZEMPIC/WEGOVY/RYBELSUS): Novo Nordisk
  • 11.2.1. Drug Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Summary of Pivotal Trials
  • 11.2.5. Clinical Development
    • 11.2.5.1. Clinical Trial Information
  • 11.2.6. Analyst's Views
• 11.3. Bexagliflozin (BRENZAVVY): TheracosBio
  • 11.3.1. Drug Description
  • 11.3.2. Regulatory Milestones
  • 11.3.3. Other Developmental Activities
  • 11.3.4. Summary of Pivotal Trials
  • 11.3.5. Clinical Development
    • 11.3.5.1. Clinical Trial Information
  • 11.3.6. Analyst's Views

12. Emerging Drugs

• 12.1. Competitive landscape of emerging therapies
• 12.2. CagriSema: Novo Nordisk
  • 12.2.1. Drug Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
    • 12.2.3.1. Clinical Trials Information
  • 12.2.4. Analyst's Views
• 12.3. Survodutide (BI 456906): Boehringer Ingelheim
  • 12.3.1. Drug Description
  • 12.3.2. Other Developmental Activities
  • 12.3.3. Clinical Development
    • 12.3.3.1. Clinical Trials Information
  • 12.3.4. Analyst's Views

13. Type 2 Diabetes Mellitus (T2DM): 7MM Analysis

• 13.1. Key Findings
• 13.2. Market Outlook of T2DM
• 13.3. Conjoint Analysis of T2DM
• 13.4. Key Market Forecast Assumptions
  • 13.4.1. Cost Assumptions
  • 13.4.2. Pricing Trends
  • 13.4.3. Analogue Assessment
  • 13.4.4. Launch Year and Therapy Uptakes
• 13.5. Total Market Size of T2DM in the 7MM
• 13.6. Total Market Size of T2DM by Therapies in the 7MM
• 13.7. The United States
  • 13.7.1. Total Market Size of T2DM in the United States
  • 13.7.2. Total Market Size of T2DM by Therapies in the United States
• 13.8. EU4 and the UK
  • 13.8.1. Total Market Size of T2DM in EU4 and the UK
  • 13.8.2. Total Market Size of T2DM by Therapies in EU4 and the UK
• 13.9. Japan
• 13.1. Total Market Size of T2DM in Japan
  • 13.9.2. Total Market Size of T2DM by Therapies in Japan

14. Unmet Needs of Type 2 Diabetes Mellitus (T2DM)

15. SWOT Analysis of Type 2 Diabetes Mellitus (T2DM)

16. KOL Views of Type 2 Diabetes Mellitus (T2DM)

17. Market Access and Reimbursement of Type 2 Diabetes Mellitus (T2DM)

• 17.1. The United States
• 17.2. EU4 and the UK
  • 17.2.1. Germany
  • 17.2.2. France
  • 17.2.3. Italy
  • 17.2.4. Spain
  • 17.2.5. United Kingdom
• 17.3. Japan
• 17.4. Summary and comparison of Market Access and Pricing Policy Developments in 2025
• 17.5. Market Access and Reimbursement of Type 2 Diabetes Mellitus (T2DM) Therapies

18. Appendix

• 18.1. Bibliography
• 18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight